UniQure Shares Surge After FDA Confirms Accelerated Review Path for Huntington's Gene Therapy

Shares of uniQure N.V. (NASDAQ: QURE) surged 6.3% in pre-market trading after the company announced a significant regulatory update for its lead gene therapy candidate and reported second-quarter financial results that surpassed revenue expectations.

FDA Confirms Path Forward for AMT-130

The primary catalyst for the stock's advance was a landmark development for its Huntington’s disease treatment, AMT-130. uniQure confirmed it received official minutes from a June 2026 Type B meeting with the U.S. Food and Drug Administration (FDA). According to the company, these minutes formalize an alignment with the agency that submitting a Biologics License Application (BLA) for AMT-130 under an accelerated approval pathway, based on existing clinical data, is reasonable.

This confirmation removes a critical regulatory overhang for investors and keeps the company on track for its planned U.S. and U.K. regulatory submissions in the third quarter of 2026. The development marks a significant turnaround after a November 2025 regulatory detour, when the FDA had previously reversed its stance on the use of external controls in the drug's study.

Financial Health and Q2 Results

Alongside the regulatory news, uniQure reported mixed but encouraging second-quarter financials. Key figures from the release include:

Ad

• Revenue: $5.84 million, beating the analyst consensus of approximately $5.49 million, driven by higher license revenue.
• Net Loss: The net loss per share was wider than anticipated, attributed to higher selling, general, and administrative expenses.

Investors appeared to prioritize the positive revenue figure and the pivotal pipeline update over the earnings miss. The company also strengthened its balance sheet with a recent $259 million follow-on offering, extending its cash runway into 2030. This provides crucial funding for the potential commercial launch of AMT-130 and further pipeline development.

Investor Outlook

For clinical-stage biotechnology firms like uniQure, progress in drug development and regulatory milestones often carries more weight for investors than quarterly financial performance. The combination of a de-risked regulatory path for its lead asset, stable revenue, and a fortified balance sheet created a convergence of positive catalysts.

CEO Matthew Kapusta called it "a defining quarter — not just for uniQure, but for the Huntington’s disease community." He reiterated that the company is "well-positioned for what will be a transformative period for uniQure and the patients we serve."